1. Kaneko S. Tirzepatide: A Novel, Once-weekly Dual GIP and GLP-1 Receptor Agonist for the Treatment of Type 2 Diabetes. Endocrinology. 2022;18(1):10–9. DOI: https://doi.org/10.17925/EE.2022.18.1.10
2. Andersen A, Lund A, Knop FK, Vilsboll T. Glucagon-like peptide 1 in health and disease. Nat Rev Endocrinol. 2018;14:390–403. Doi: 10.1038/s41574-018-0016-2.
3. Seino Y, Fukushima M, Yabe D. GIP and GLP-1, the two incretin hormones: Similarities and differences. J Diabetes Investig. 2010 Apr 22;1(1-2):8-23. doi: 10.1111/j.2040-1124.2010.00022.x. PMID: 24843404; PMCID: PMC4020673.
4. Campbell JE, Drucker DJ. Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab. 2013;17:819–37.DOI: 10.1016/j.cmet.2013.04.008
5. Samms RJ, Sloop KW, Gribble FM, et al. GIPR function in the central nervous system: Implications and novel perspectives for GIP-based therapies in treating metabolic disorders. Diabetes. 2021;70:1938–44. Doi: 10.2337/dbi21-0002.
6. Heimburger SMN, Nielsen CN, Calanna S, et al. Glucose-dependent insulinotropic polypeptide induces lipolysis during stable basal insulin substitution and hyperglycaemia in men with type 1 diabetes: A randomized, double-blind, placebo-controlled, crossover clinical trial. Diabetes Obes Metab. 2022;24:142–7. Doi: 10.1111/dom.14545.
7. Lee MMY, Ghouri N, McGuire DK, et al. Meta-analyses of results from randomized outcome trials comparing cardiovascular effects of SGLT2is and GLP-1RAs in Asian versus white patients with and without type 2 diabetes. Diabetes Care.2021;44:1236–41. Doi: 10.2337/dc20-3007.
8. Husain M, Bain SC, Jeppesen OK, et al. Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk. Diabetes Obes Metab. 2020;22:442–51. Doi: 10.1111/dom.13955
9. Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375:311–22. Doi: 10.1056/NEJMoa1603827
10. Zhang ZQ, Holscher C. GIP has neuroprotective effects in Alzheimer and Parkinson’s disease models. Peptides. 2020;125:170184.doi: 10.1016/j.peptides.2019.170184.
11. Deacon CF, Nauck MA, Meier J, et al. Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide. J Clin Endocrinol Metab. 2000;85:3575–81. Doi: 10.1210/jcem.85.10.6855.
12. Killion EA, Wang J, Yie J, et al. Anti-obesity effects of GIPR antagonists alone and in combination with GLP-1R agonists in preclinical models. Sci Transl Med. 2018;10:eaat3392. Doi: 10.1126/scitranslmed.aat3392.
13. Kaneko S. Novel approaches to pharmacological management of type 2 diabetes in Japan. Expert Opin Pharmacother. 2021;22:2235–49.doi: 10.1080/1465666.2021.1974401.
14. Frias JP, Nauck MA, Van J, et al. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: A randomised, placebo-controlled and active comparator-controlled phase 2 trial. Lancet. 2018;392:2180–93. Doi:10.1016/S0140-6736(18)322260-8.
15. Frias JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021;358:503–15.doi: 10.1056/NEJMoa2107519
16. Del Prato S, Kahn SE, Pavo I, et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): A randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet. 2021;398:1811–24. Doi: 10.1016/S0140-6736(21)02188-7
17. Sattar N, McGuire DK, Pavo I, et al. Tirzepatide cardiovascular event risk assessment: A pre-specified meta-analysis. Nat Med. 2022;28:591–8. Doi: 10.1038/s41591-022-01707-4
Facebook 
Masuk dengan Email
